Telix Pharmaceuticals (ASX:TLX) has moved to bolster its board and leadership succession plans with the appointment of veteran healthcare executive David Gill as a non-executive director.
The Melbourne-headquartered radiopharmaceutical company announced that Gill will join the board effective May 11, 2026, with expectations that he will assume the role of chair in due course. The transition will see current chair Mark Nelson step back into a non-executive director position, maintaining continuity while enabling a planned leadership handover.
Gill brings more than three decades of experience across the biopharmaceutical and medical device sectors, including senior leadership roles in publicly traded companies and extensive board-level oversight. His background in capital markets, operational scaling, and corporate turnaround makes him a strong strategic addition as Telix expands its global footprint and governance complexity.
Welcoming the appointment, interim chair Mark Nelson underscored the strategic value of Gill’s expertise, stating, “We are pleased to welcome David to the Board, where his strong financial expertise and deep knowledge of U.S. capital markets will be highly valuable. We intend to further strengthen the Board through additional appointments aligned with our growth trajectory and governance needs as a dual-listed company.”
The board changes come as Telix continues to scale internationally, with operations spanning the United States, Europe, Japan and Latin America, and a growing focus on commercialising radiopharmaceuticals targeting oncology and rare diseases.
Telix also confirmed a transition in its company secretariat. Genevieve Ryan has stepped down from the role, and the company has acknowledged her contributions since late 2022. Shomalin Naidoo has been appointed on an interim basis while a permanent replacement is sought.